Autoimmunity to membrane proteins in the central nervous system has been increasingly recognized as a cause of neuropsychiatric disease. A key recent development was the discovery of autoantibodies to N-methyl-d-aspartate (NMDA) receptors in some cases of encephalitis, characterized by cognitive changes, memory loss, and seizures that could lead to long-term morbidity or mortality. Treatment approaches and experimental studies have largely focused on the pathogenic role of these autoantibodies. Passive antibody transfer to mice has provided useful insights but does not produce the full spectrum of the human disease. Here, we describe a de novo autoimmune mouse model of anti-NMDA receptor encephalitis. Active immunization of immunocompetent mice with conformationally stabilized, native-like NMDA receptors induced a fulminant encephalitis, consistent with the behavioral and pathologic characteristics of human cases. Our results provide evidence for neuroinflammation and immune cell infiltration as components of the autoimmune response in mice. Use of transgenic mice indicated that mature T cells and antibody-producing cells were required for disease induction. This active immunization model may provide insights into disease induction and a platform for testing therapeutic approaches.
INTRODUCTION
Behavioral changes, psychosis, memory impairment, and seizures have been recognized as a pattern in several forms of encephalitis (1) . In some cases, this discrete clinical syndrome has been attributed to herpes simplex virus, but the underlying cause in other cases has remained unknown. In 2007, autoantibodies targeting N-methyl-daspartate (NMDA) receptors were found in a subset of these patients (2, 3) . NMDA receptors are ligand-gated Ca2 + permeable ion channels expressed postsynaptically at excitatory synapses in neurons throughout the central nervous system (CNS). These receptors play critical roles in synaptic plasticity and development, while NMDA receptor antagonists disrupt memory formation and cause schizophrenia-like symptoms (4) (5) (6) (7) . Thus, loss of function of these receptors can lead to both structural and functional changes in the brain (8) (9) (10) . NMDA receptors are heterotetrameric composed of two obligate GluN1 subunits and two variable GluN2 subunits (GluN2A-D) arranged around a central pore. GluN1/GluN2A/GluN2B triheteromers are the most common subunit combination in forebrain excitatory neurons (4, 11) . With recognition of anti-NMDA receptor encephalitis as a clinical syndrome, diagnostic tests have revealed that the disease is relatively common across a broad range of ages (12) (13) (14) (15) (16) . Initially considered as one of the paraneoplastic disorders, it is now clear that many affected patients do not have detectable tumors (12, 17) , underscoring our lack of understanding of the disease etiology. Patient-derived serum or cerebrospinal fluid (CSF) indicates a role for antibodies directed at NMDA receptor subunits in the pathogenesis, leading to treatments to reduce antibody titers with plasmapheresis or immunosuppression (15) . However, recovery after standard treatments can be prolonged and incomplete (12, (18) (19) (20) .
Passive transfer of antibodies from affected patients to mice has indicated that NMDA receptor antibodies can cause hypofunction in NMDA receptor-mediated synaptic transmission (17, (21) (22) (23) ). Yet, the initiating immunological factors and the potential role of immune cell infiltrates and neuroinflammation in the disease process are difficult to determine using existing models (21, (24) (25) (26) . A robust animal model of the disease has the potential to address such issues.
To develop a mouse model of autoimmune encephalitis, we postulated that immunization with fully assembled receptors could be important in triggering the disease. Thus, we used active immunization with intact native-like NMDA receptors composed of GluN1-GluN2B tetramers embedded in liposomes. Subcutaneous injection of these NMDA receptor-containing proteoliposomes induced fulminant encephalitis within 4 weeks in young adult mice. The mice demonstrated behavioral changes, seizures, and histological features of neuroinflammation and immune cell infiltration that were most prominent in the hippocampus. The presence of NMDA receptor antibodies was confirmed by immunohistochemistry (IHC) and Western blot. CD4 + T cell infiltration was an early feature, and both mature T cells and B cells were required for disease induction. protein complexes and for facilitating an antigen-specific antibody response (27) (28) (29) (30) (31) (32) (33) (34) (35) . The native-like conformation of NMDA receptors in our proteoliposome preparation was validated in a recent cryogenic electron microscopy study in which the same method was used to resolve the structure of tetrameric NMDA receptors with atomic precision (34) .
Using a standard immunization protocol, mice received a subcutaneous injection of NMDA receptors in proteoliposomes (see Methods for protein/liposome ratio and injection volume), followed by a booster 2 weeks later (36) . Littermate control cohorts were injected only with liposomes or with saline. Overt neurological signs began to appear by 4 weeks, and by 6 weeks after immunization, nearly all of the proteoliposome-treated mice (86%) exhibited abnormal home cage behavior (Fig. 1B) .The most prominent behavioral changes were hyperactivity (86%), followed by tight circling (50%), overt seizures (21%), and hunched back/lethargy (11%) (Fig. 1C and movies S1 to S5). Cumulative clinical scores (described in Methods) were significantly higher in proteoliposome-treated mice [P < 0.0001 (proteoliposome versus liposome), P < 0.0001 (proteoliposome versus saline), and P > 0.9999 (liposome versus saline); Kruskal-Wallis test with Dunn's multiple comparisons post hoc; n = 28 per treatment group; Fig. 1B ]. Proteoliposome-treated mice also had increased mortality by 6 weeks after immunization (n = 8 of 56 proteoliposomes and n = 0 of 56 controls; P < 0.0005; log-rank test; Fig. 1D ). The results were not limited to the specific holoprotein, as we observed a similar distribution of clinical signs in mice immunized with a rat GluN1-GluN2A proteoliposome preparation (50% hyperactivity, 20% circling, 20% seizure, and 10% hunching/lethargy; n = 10; fig. S1A ).
To assess behavioral phenotype, we used a battery of standardized tests. Open-field testing ( Fig. 2A) confirmed a hyperactive locomotor phenotype with nearly double the distance traveled in proteoliposome-treated mice [proteoliposome = 5472 ± 525.4 cm (n = 26), liposome = 3207 ± 111 cm (n = 28), and saline = 3093 ± 84.9 cm (n = 28); P = 0.0002 (proteoliposome versus liposome), P < 0.0001 (proteoliposome versus saline), and P > 0.9999 (liposome versus saline); Kruskal-Wallis test with Dunn's multiple comparisons post hoc]. Proteoliposometreated mice also showed a high degree of variability in the open field ranging from near immobility to extreme hyperactivity. Nest building, indicative of complex stereotyped behavior, was severely compromised in the proteoliposometreated mice (Fig. 2B) . At 6 weeks after immunization, control mice created precise nests, whereas proteoliposometreated mice barely disturbed the nestlets as indicated by lower nesting scores at 24 and 48 hours, respectively: proteoliposome = 1 ± 0.29 and 1.48 ± 0.39 (n = 27), liposome = 4.60 ± 0.14 and 4.78 ± 0.11 (n = 28), and saline = 4.21 ± 0.14 and 4.75 ± 0.12 (n = 28) [24 hours: P < 0.0001 (proteoliposome versus liposome), P < 0.0001 (proteoliposome versus saline), and P = 0.3603 (liposome versus saline); 48 hours: P < 0.0001 (proteoliposome versus liposome), P < 0.0001 (proteoliposome versus saline), and P > 0.9999 (liposome versus saline); Kruskal-Wallis with Dunn's multiple comparisons post hoc]. In the zero maze, often used as a measure of anxiety-like behavior, proteoliposome-treated mice spent more time in the normally aversive open area [percentage of time in the open area: proteoliposome = 27.90 ± 3.70 (n = 18), liposome = 16.08 ± 0.71 (n = 28), and saline = 16.32 ± 0.96 (n = 28); P = 0.0065 (proteoliposome versus liposome), P = 0.0081 (proteoliposome versus saline), and P > 0.9999 (liposome. versus saline); Kruskal-Wallis with Dunn's multiple comparisons post hoc; Fig. 2C ]. There was no statistical difference in the total distance moved in the open or closed areas, indicating that hyperactivity could not explain the observed phenotype [open area: proteoliposome = 175.4 ± 26.18 cm, liposome = 118.7 ± 9.41 cm, and saline = 130.4 ± 15.67 cm (P = 0.0786, proteoliposome versus liposome; P = 0.0629, proteoliposome versus saline; and P > 0.9999, liposome versus saline); closed area: proteoliposome = 572.6.4 ± 27.29 cm, liposome = 494.8 ± 17.83 cm, and saline = 524.1 ± 22.17 cm (P = 0.1140, proteoliposome versus liposome; P = 0.4312, proteoliposome versus saline; and P > 0.9999, liposome versus saline); Kruskal-Wallis with Dunn's multiple comparisons post hoc; Fig. 2C ]. These results indicated that immunization with NMDA receptor holoprotein induces a behavioral phenotype compatible with encephalitis based on the criteria used to diagnose anti-NMDA receptor encephalitis in humans (13) .
Neuroinflammation and peripheral leukocyte infiltration
The histopathology of reported cases of human anti-NMDA receptor encephalitis is heterogeneous and can include immune cell infiltrates, 
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neuroinflammation, and occasionally neuronal loss (24) (25) (26) 37) . In proteoliposome-treated mice at 6 weeks after immunization, hematoxylin and eosin (H&E)-labeled perivascular cuffing was observed in multiple CNS regions including the hippocampus and neocortex of five of the six mice examined [perivascular cuffing measure: proteoliposome = 0.83 ± 0.17 and control = 0 ± 0; P = 0.0152 (proteoliposome versus control), Mann-Whitney test; n = 6 per group]. Representative images of perivascular cuffing are shown in Fig. 3A (right) . Patchy areas of cell death were observed in brain sections in one of the six mice included in the histological analysis [cell death measure: proteoliposome = 0.17 ± 0.17 and control = 0 ± 0; P > 0.9999 (proteoliposome versus control), Mann-Whitney test; n = 6 per group]. Figure 3B (right) shows areas of cell death in a proteoliposome-treated mouse. No evidence of inflammation or cell death was present in assessed H&E controls (Fig. 3, A and B, left) . Individual data points from the H&E assay and all subsequent experiments with an n < 20 are included in table S1.
Immunolabeling with glial fibrillary acidic protein (GFAP) and Iba1 revealed an inflammatory response in assessed proteoliposome-treated mice at 6 weeks after immunization (Fig. 4, A By 6 weeks after immunization, there was also pronounced CNS infiltration by peripheral immune cells in the proteoliposome-treated mice assessed by IHC. Labeling with the pan-leukocyte marker CD45R was robust in the hippocampus, striatum, thalamus, amygdala, and neocortex of these mice ( , and B cells (CD20 + ) were increased in the brains of assessed proteoliposometreated mice as well, whereas cytotoxic T cells (CD8 + ) were sparse or absent (Fig. 5B, right) . In contrast liposomeor saline-treated mice assessed by IHC lacked immunoreactivity to the same immune cell markers [P = 0.0022 (proteoliposome versus liposome), Mann-Whitney test; n = 6 per group, for all immune cells analyzed; Fig. 5 , B and C]. Mean cell densities for control-and proteoliposome-treated mice included in the preceding analyses are summarized in Table 1, with individual  values provided in table S1 .
Although mice examined at 3 weeks after immunization did not show prominent clinical features, neuroinflammation, and immune cell infiltration could be detected in some animals at this early time point (Table 1 and fig. S2 , A to E). Figure S2 (B to E) shows representative images and quantification of glial markers and immune cell infiltrates. Quantification of GFAP and Iba1 immune reactivity at 3 weeks after immunization showed no significant differences between treatment groups despite evidence of glial nodules in proteoliposome-treated mice [GFAP fluorescence Table 1 and table S1 contain means and individual values, respectively, for all immune cell quantifications at the 3-week time point.
Receptor autoantibodies in serum from proteoliposome-treated mice
To assess the specificity of the immunoglobulin G (IgG) isolates from the serum of proteoliposome-treated mice, we used human embryonic kidney (HEK) 293 cells to express and stain for NMDA receptor subunits. HEK cells were transfected with single subunit constructs or combinations of GluN1/GluN2A and GluN1/ GluN2B. Using this HEK cell assay, we tested all serum/IgG isolates from proteoliposome-treated mice included in the behavioral and IHC analyses. We observed colabeling of NMDA receptor-expressing HEK293 cells using a commercially available GluN1 antibody and IgG derived from all proteoliposome-treated mice at 6 weeks after immunization, with no colabeling seen in serum/IgG isolates from a randomly selected group of controls [proteoliposome = 1 ± 0 and control = 0 ± 0; P < 0.0001 (proteoliposome versus control), Mann-Whitney test; n = 26 per group]. Figure 6A (bottom) shows representative images of HEK cells coimmunolabeled with a GluN1 antibody and IgG derived from a proteoliposometreated mouse at 6 weeks after immunization. We used the same HEK cell assay to assess the serum from a cohort of mice at 3 weeks after immunization (fig S3) . At the 3-week time point, all but one proteoliposome-treated mouse showed colabeling with a GluN1 antibody, indicating the presence of antibodies before we observed overt clinical signs [proteoliposome = 0.80 ± 0.20 and control = 0 ± 0; P = 0.0476 (proteoliposome versus control), Mann-Whitney test; n = 5 per group]. Figure S3A shows representative HEK cell colabeling for a GluN1 antibody and IgG from a proteoliposome-and controltreated mouse at 3 weeks after immunization. To ensure that the colabeling observed in our HEK cell assay was specific for the GluN1 subunit, we repeated the staining in HEK cells expressing only the GluN1 subunit with a subset of serum/ IgG samples from each treatment condition. Again, IgG derived from each proteoliposome-treated mouse included in the assay colabeled with a GluN1 specific antibody at 6 weeks after immunization [proteoliposome = 1 ± 0 and control = 0 ± 0; P = 0.0286 (proteoliposome versus control), Mann-Whitney test; n = 4 per group; fig. S4A ]. Serum samples derived from all mice treated with rat GluN1-GluN2A proteoliposomes also showed GluN1-specific colabeling, with no colabeling observed in controls at 6 weeks after immunization [proteoliposome = 1 ± 0 and liposome = 0 ± 0; P < 0.0001 (proteoliposome versus liposome), Mann-Whitney test; n = 10 proteoliposomes and 8 liposomes; figs. S1C and S4B (HEK GluN1-GluN2A and HEK GluN1 only, respectively)]. Individual values from all HEK293 cell assays are shown in table S1.
In cultured mouse hippocampal neurons [days in vitro (DIV) 14 to DIV 21], only the IgG isolate from proteoliposome-treated mice colocalized with a GluN1 subunit-specific antibody in IgG samples derived from proteoliposome-treated mice at both the 6-and 3-week time points [neuron ICC (immunocytochemistry): P < 0.0001 (proteoliposome versus control) and P = 0.0476 (proteoliposome versus liposome), at 6-week (n = 26 per group) and 3-week (n = 5 per group) time points, respectively, by Mann-Whitney test]. The punctate labeling that we observed along dendrites and at dendritic spines follows the expected distribution of NMDA receptors at synapses (4, 8, 38, 39) . Figure 6B shows colabeling of proteoliposome-derived IgG (6 weeks after immunization) and a GluN1 antibody along a dendritic shaft. Figure S3B shows the same colabeling for proteoliposome IgG from the 3-week time point. Hippocampal NMDA receptors are triheteromeric, composed of GluN1, GluN2A, and GluN2B subunits, and are widely distributed in the neuropil (40, 41) . As a demonstration of the tissue distribution of proteoliposome-derived IgG labeling, we examined IgG staining pattern in naïve mouse brain sections as compared to the pattern of a GluN2A subunit-specific antibody, which was effective in these floating tissue sections (6 weeks after immunization; Fig. 6C ). In the samples that we tested in this assay, purified IgG (red) from liposome controls showed no labeling, whereas proteoliposome-derived IgG (red) showed the same staining pattern as the NMDA receptor antibody (green) [proteoliposome = 1 ± 0 and control = 0 ± 0; P = 0.0286 (proteoliposome versus control), Mann-Whitney test; n = 4 per group]. Staining for mouse IgG as a proxy for the presence of autoantibodies outlined the hippocampi of mice included in this assay ( fig. S5) , consistent with the expected high levels of NMDA receptor expression in hippocampus and the IgG deposits observed in anti-NMDA receptor encephalitis (proteoliposome = 1 ± 0 and control = 0 ± 0; n = 3 per group) (2, 21) .
To confirm the NR1 labeling in the HEK293 cell assays from each mouse, we used serum from two proteoliposome-treated and two liposome-treated mice at 6 weeks after immunization to examine bands on Western blots. Bands corresponding to purified recombinant rat and Xenopus GluN1 subunit protein, as well as Xenopus GluN2B, were observed. Although a putative pathogenic epitope on the GluN1 amino-terminal domain (ATD) has been identified in some human cases, immunoreactivity to GluN2A and GluN2B subunits has been also reported in a subset of cases (2, 17, 42, 43) . For the mouse shown in Fig. 6D , serum also labeled a Xenopus GluN1 subunit that lacked the ATD domain, suggesting the presence of polyclonal antibodies in at least some of the mice. Serum from control-treated mice included in Western blot did not recognize NMDA receptor subunits (proteoliposome = 1 ± 0 and liposome = 0 ± 0; n = 2 per group; Fig. 6A, middle) .
Serum from proteoliposome-treated mice did not acutely block NMDA receptor function, as assessed by whole-cell currents in cultured hippocampal neurons (Fig. 7, A and B) . NMDA (50 M) was coapplied by local flow pipes either with serum from liposometreated mice or with serum from proteoliposome-treated mice (1:100 dilution). The NMDA-evoked current in the presence of serum from proteoliposome-treated mice was 95.9 ± 6.8% of that evoked by the combination of NMDA and serum from liposometreated mice in the same neuron [P = 0.23, paired t test (n = 8); P = 0.2231 (proteoliposome serum) and P = 0.1413 ( liposome serum), Shapiro-Wilk normality test]. In contrast, a 24-hour incubation with serum from proteoliposome-treated mice reduced synaptically activated NMDA receptors, which underlie the slow components of excitatory postsynaptic currents (EPSCs) and drive overall network activity. As shown in Fig. 7C (top left) , the slow components of EPSC barrages from neurons incubated in serum from liposome-treated mice were reduced by the NMDA receptor antagonist, D-AP5, as indicated by the rapid decay of the spontaneous EPSCs (sEPSCs; Fig 7C, top right) . However, after 24-hour incubation in serum from proteoliposome-treated mice, sEPSCs had reduced NMDA receptor-mediated currents and thus were less sensitive to block by D-AP5 (Fig. 7C , bottom right). For neurons incubated in serum from liposome-treated mice, total charge from sEPSCs was reduced to 44.1 ± 7.9% of control charge by D-AP5 (Fig. 7D) . In contrast, D-AP5 reduced total charge to only 85.6 ± 6.0% of control charge in neurons incubated with serum from proteoliposome-treated mice [P < 0.005, paired t test (n = 8 per group); P = 0.3893 (proteoliposome serum) and P = 0.5722 (liposome serum), Shapiro-Wilk normality test; Fig. 7D ]. These results demonstrate a marked reduction in NMDA receptor function after 24-hour incubation with serum from proteoliposome-treated mice. We also stained the same 24 hour-treated cultures for postsynaptic density-95 protein (PSD-95), a key structural component and marker of dendritic spines at excitatory synapses, and GluN1 to assess their colocalization ( Fig. 7E) (44) . The 24-hour incubation did not affect total synaptic puncta but did result in a decrease of >50% in GluN1 immunoreactivity ( 
T cells and B cells are necessary for proteoliposome-induced encephalitis
Studies of anti-NMDA receptor encephalitis in human cases have focused on the role of antibodies (2, 21, 22) . Our results in proteoliposometreated mice are consistent with the presence of B cell infiltrates and NMDA receptor autoantibodies. In human cases, perivascular T cell infiltrates, primarily CD4 + helper T cells, have been reported; however, parenchymal infiltrates appear to be infrequent (21, 24) . To distinguish the roles of B cells and T cells in proteoliposome-treated mice, we used two well-characterized mutant mouse lines that lack either mature B cells or mature T cells (45, 46) . Consistent with a role for B cells in the pathophysiology, proteoliposome treatment of MuMt (Fig. 8A) . Likewise, Tcr − mice did not show histopathological evidence of gliosis or 
DISCUSSION
Our results demonstrate that active immunization with NMDA receptor holoproteins induces a disease state in mice that recapitulates the core features of human anti-NMDA receptor encephalitis including the presence of pathogenic anti-GluN1 autoantibodies (13) . In general, active immunization to develop animal models has played an important role in the study of neurological disorders including autoimmune diseases such as myasthenia gravis and multiple sclerosis (47, 48) . For example, peptide fragments from myelin have long been used to generate experimental autoimmune encephalomyelitis with its incumbent clinical signs to test the molecular basis and therapeutic approaches in multiple sclerosis (47, 49, 50) . Likewise, active immunization with neuromuscular junction proteins can cause myasthenic-like features in mice (51) . Although synaptic membrane proteins have been implicated in autoimmune encephalitis, studies of these diseases have largely been limited to passive transfer approaches (1). Our de novo autoimmune anti-NMDA receptor encephalitis model represents an additional approach to examining the pathophysiology and developing treatments for the human disease. The etiology in some cases of encephalitis was an enigma for decades. The discovery of NMDA receptor antibodies in a subset of these patients not only was a surprise but also provided an opportunity for a better understanding of the causes and treatment strategies as well (17) . The diagnostic criteria used to identify anti-NMDA receptor encephalitis (13) include a number of features that were also present in our mouse model including behavioral changes, movement abnormalities, seizures, and the presence of antibodies against the GluN1 subunit of NMDA receptors. The clinical signs and histopathology ranged from mice with marked behavioral impairments to occasional mice that lacked clinical signs but had histological features and anti-NMDA receptor antibodies. As shown in the HEK293 cell assays, all proteoliposome-treated mice had antibodies to GluN1 at 6 weeks after immunization, but in those mice tested by Western blot, we also saw immunoreactivity to GluN2B or to a construct that lacked the ATD of GluN1. This pattern suggests the possibility of a polyclonal response by the time fulminant symptoms were present (6 weeks after immunization). This issue and the possibility of epitope spreading will be important to examine in the future. However, consistent with the human disease, a GluN1 epitope was predominant.
Antibodies recognizing NMDA receptor subunits have been observed in some other contexts. For example, systemic lupus erythematosus (SLE) is associated with a range of antibodies to nuclear antigens and antibodies recognizing the NMDA receptor GluN2A subunit (52, 53) . However, unlike the NMDA receptor antibodies found in our mice and in patients with human anti-NMDA receptor encephalitis, anti-GluN2A/B antibodies derived from patients with SLE do not appear to alter synaptic responses but rather induce cell death (52, 53) .
Although histopathological reports are available for only a small fraction of human cases of anti-NMDA receptor encephalitis, immune cell infiltrates and neuroinflammation have been observed in some patients (21, 24) but were less prominent in other cases (26) . The presence or absence of inflammatory cell infiltrates thus likely depends on the time point at which the tissue is examined. Neuroinflammation in our mice was most prominent during the fulminant stages of the disease (6 weeks after immunization compared to 3 weeks). In the human disease and in our mouse model, cytotoxic T cell involvement can occur but was not a prominent feature in mice included in this assessment (24) (25) (26) 37) . In addition, consistent with human cases, IgG infiltration of the hippocampus could be seen in proteoliposome-treated mice in which tissue slices were incubated with anti-IgG antibodies (2, 21) .
Previous experimental studies of anti-NMDA receptor encephalitis used passive transfer approaches with patient-derived CSF/IgG (21) (22) (23) 54) . These studies provide compelling evidence for the involvement of NMDA receptor antibodies in pathogenesis (22, 23, 43, 54) . Intraventricular infusion of human NMDA receptor antibodies in mice decreased NMDA receptor density in the hippocampus (23, 55) , but these mice did not exhibit movement disturbances or spontaneous seizures (23, (55) (56) (57) . These observations suggest that passive infusion of NMDA antibodies is not sufficient to fully mimic the clinical syndrome. Although no animal model is expected to perfectly mimic a human disease, our results indicate that active immunization of immunocompetent mice with NMDA receptor holoproteins replicates several signs of human encephalitis. The active immunization model also allows an examination of the time course of the disease process from the point of induction.
The current hypothesis for the clinical phenotype is that antibodymediated internalization of NMDA receptors leads to hypofunction at a network level. The available evidence suggests that antibodies from human cases cause internalization of NMDA receptors in vitro and reduce NMDA responses (21, 22, 58) . Thus, therapies in use or proposed have been directed at removing antibodies, inhibiting immunosuppression, or preventing receptor internalization (1). The hypofunction hypothesis gains further support from the behavioral side effects observed with the use of NMDA receptor antagonists, but general NMDA receptor hypofunction does not easily account for the presence of unprovoked, spontaneous seizures given the presence of NMDA receptors on both excitatory and inhibitory neurons and the complexity of the circuits involved (6, 22, 56, 59, 60) . More experiments will be necessary to the relative contribution of receptor internalization to neurological signs and whether other factors contribute to the spectrum of clinical signs and histopathology.
Although previous studies of anti-NMDA receptor encephalitis have largely focused on the role of B cells and antibodies, the role of CD4 + T cells in autoimmune encephalitis is an area of growing interest (61) . T cells could promote neuroinflammation and potentiate B cell-and plasma cell-mediated antibody responses. In human cases, CSF cytokine/chemokine profiles support a role for CD4 + T cell involvement (62) (63) (64) (65) . For example, interleukin-17 (IL-17), a proinflammatory cytokine produced by T helper 17 CD4 + T cells, is prominent in the CSF of human cases and may perform the dual role of bloodbrain barrier disruption and up-regulation of IL-6, a pro-B cell and plasma cell cytokine (62, 66, 67) . Although cytotoxic T cells were not a prominent histological feature in our mice, the absence of disease in the Tcr − mice lacking mature CD4 + or CD8 + cells supports an important role for some population of T cells in disease pathogenesis. Thus, therapies designed to reduce T cell-mediated inflammation, such as blocking IL-17 signaling, as well as those aimed at reducing B cell activation, are worthy of further investigation.
The trigger for an autoimmune reaction to NMDA receptors remains unclear. Immunization using peptide fragments to produce NMDA receptor antibodies has not resulted in reports of clinical disease. In a recent study, mice immunized with NMDA receptor peptides did not show clinical signs, but the authors suggested that blood-brain barrier integrity may prevent circulating NMDA receptor antibodies from entering the CNS (68) . The immunogens in our case were the tetrameric Xenopus laevis GluN1/GluN2B or rat GluN1/GluN2A receptor in native-like heteromeric assembly (69) . The X. laevis subunits had been altered to maximize protein stability, by removal of the intracellular C termini (69) , and were capable of binding glutamate or glycine, which may also have improved protein stability. The rat subunits that we used had no mutations except for removal of the intracellular C termini and thus unaltered topology in the ATD, one of the putative sites of pathogenic antibody interactions in human cases (42, 43) . The use of holoprotein immunogens with intact extracellular domains likely played a role in the high incidence of disease in our mice and may be relevant considerations for other membrane proteins implicated as causes of encephalitis. Our results suggest that disease induction depends on conformationally restricted epitopes. This idea is consistent with previous studies in HEK293 cells, which showed that an assembled NMDA receptor was necessary for reactivity of antibodies from human cases (2, 17) . In human cases, the source of intact NMDA receptors to trigger the autoimmune response is unknown, but it could be ectopic expression from a tumor or membrane debris after an insult causing neuronal cell loss. For example, anti-NMDA receptor encephalitis has been reported after viral infection (12, 70) . An association with viral infection was also suggested in the case report of Knut, a polar bear at the Berlin zoo (71) .
Despite the prevalence of anti-NMDA receptor encephalitis, many experimental questions remain unanswered given the lack of a de novo autoimmune animal model that recapitulates the signs and symptoms. The mouse model described here provides such a platform and has already provided several new insights. For example, the use of conformationally stabilized holoproteins appears to be a critical component of immunogenicity, and our results already indicate a complex pathogenesis. Thus, the initial steps in disease induction, the roles of specific immune components, and potential new therapies can now be tested.
In the future, it will be interesting to examine immunized mice at earlier time points to look for specific memory deficits, more subtle cognitive impairments, and the evolution and atomic localization of autoantibody epitopes. We did not examine some other aspects that have been reported in the human disease such as autonomic dysfunction or the cause of death in some of our mice. Furthermore, we did not investigate aberrant electrophysiological activity at the network and synaptic level in vivo or in brain slices derived from affected mice. However, these questions are all addressable using this mouse model, which offers significant advantages for further exploration of such issues.
METHODS

Study design
We examined the effect of active immunization with NMDA receptor native-like holoproteins on normal adult mice. The aim of the study was to investigate autoimmunity to NMDA receptors in the context of anti-NMDA receptor encephalitis. Littermate controls (liposome or saline) of both sexes were used for all interventions. Results from liposome and saline controls did not differ and were thus combined for statistical analysis of "control" in some experiments as indicated. Criteria were established in advance on the basis of the pilot studies for issues including data inclusion, outliers, selection of end points, and sample size (see the "Statistics" section). All analyses were blinded. Observations within each animal were averaged, and the value for n replicates reflects the number of animals. Detailed methods for each experimental technique and analysis are included in the Supplementary Materials including animal use, NMDA receptor expression and purification, NMDA receptor proteoliposome preparation and immunization, behavioral assessments, histology and IHC, serum collection/IgG purification and Western blots, in vitro assays and IHC, and electrophysiology and quantification of synaptic puncta.
Statistics
Sample size was determined on the basis of previous experiments of this type, with an effect size of 20% and a power of 0.8. Tests of normality were used to determine the appropriate test. Multiple comparisons used one-or two-way analysis of variance (ANOVA) or nonparametric ANOVA as indicated for each experiment. Exact P values are provided, and both the number of animals and the number of observations are indicated as appropriate. Data unless otherwise indicated are plotted as means ± SEM. All statistical analyses were completed using Prism 7 software (GraphPad). Table S1 . Individual values for all analyses with n < 20. Movie S1. Representative liposome-treated control mouse in home cage. Movie S2. Proteoliposome-treated mouse with locomotor hyperactivity. Movie S3. Proteoliposome-treated mouse with aberrant circling. Movie S4. Proteoliposome-treated mouse during a clinical seizure. Movie S5. Proteoliposome-treated mouse with prominent hunched back and lethargy.
SUPPLEMENTARY MATERIALS
